Development of Universal Antivenom Using Display Phage
Abstract
Snake bites are a global health concern, impacting millions of people each year, particularly those in remote and underdeveloped areas. Due to the high probability of military operations occurring in these regions, new innovations are necessary to ensure that our troops have the means to effectively combat snakebite envenomations in remote, austere locations where prolonged evacuations are likely. Most commercially available antivenoms utilize antibodies which are developed by exposing animals to venoms for immunological conditioning, which can take up to 12 months. These antibodies are not always efficient at inhibiting venom activity, and require specialized storage conditions prior to use. There is a need for antivenoms that are capable of: (1) rapid production at low cost, (2) maximizing efficacy, (3) long-term storage in liquid form and extreme temperatures, and (4) minimal adverse reactions. We propose the use of selected phage-expressed peptides to target, bind, and neutralize snake venom. M13 phages are stable in pH 3-11, resistant to extreme temperatures, and can be effectively stored in a liquid form, allowing for immediate, easy administration. This will provide a more stable, simple to transport, and quick to administer alternative to antibody based antivenoms.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 18, 2018
- Source ID
- HU00011710046
Entities
People
- Elda Sanchez
Organizations
- Texas A&M University–Kingsville
- Uniformed Services University of the Health Sciences